Isorhamnetin Modulates Drug-Resistance-Related Biomarkers in Colon Cancer Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136208 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nikola Radenković und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Ecology, Faculty of Science, University of Kragujevac, Radoja Domanovića 12, 34000 Kragujevac, Serbia. Hauptthemen laut MEDLINE: Quercetin, Drug Resistance, Neoplasm, Colonic Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation of the Republic of Serbia, Center for Scientific Research of the Serbian Academy of Sciences and Arts and the University of Kragujevac.
Abstract (Originalsprache)
The development of resistance to standard cytostatics, such as 5-fluorouracil (5-FU), significantly limits the efficacy of colon cancer therapy, prompting the search for novel anticancer agents, particularly among natural compounds. This study evaluated the anticancer effects of isorhamnetin, a plant-derived flavonol, and its ability to modulate the expression of drug-resistance-related biomarkers in SW-480 and HT-29 colon cancer cells, with a focus on ATP-binding cassette (ABC) transporters. Isorhamnetin demonstrated strong cytotoxic and proapoptotic activity on both cell lines, while showing lower toxicity toward normal HaCaT cells. In addition to suppressing the mRNA expression of drug-metabolizing enzymes (CYP1A1 and CYP1B1), isorhamnetin significantly reduced the mRNA levels of multidrug resistance-associated proteins 1 and 5 (MRP1 and MRP5), as well as the P-glycoprotein (P-gp) level in SW-480 and HT-29 cells. Molecular docking analysis revealed a high binding affinity of isorhamnetin to CYP1A1, CYP1B1, P-gp, MRP1, MRP5, and glutathione S-transferase (GST) proteins, with stronger interactions than those observed for 5-FU, suggesting potential interference with their function. These results provide a solid basis for future investigations to confirm the therapeutic potential of isorhamnetin as a modulator of drug resistance in colon cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Ecology, Faculty of Science, University of Kragujevac, Radoja Domanovića 12, 34000 Kragujevac, Serbia.
- Department of Natural Sciences, Institute for Information Technologies Kragujevac, University of Kragujevac, Jovana Cvijića bb, 34000 Kragujevac, Serbia.
- Department of Neurobiology, Institute for Biological Research "Siniša Stanković", University of Belgrade, Bulevar Despota Stefana 142, 11060 Belgrade, Serbia.
ORCID-Profile: Nikola Radenković, Dejan Milenković, Danijela Nikodijević, Sofija Jovanović Stojanov, Milena Milutinović
Förderung
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia
- Center for Scientific Research of the Serbian Academy of Sciences and Arts and the University of Kragujevac
Zitieren
APA
Radenković, N., Milenković, D., Nikodijević, D., Jovanović Stojanov, S., Podolski Renić, A., & Milutinović, M. (2025). Isorhamnetin Modulates Drug-Resistance-Related Biomarkers in Colon Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136208
Vancouver
Radenković N, Milenković D, Nikodijević D, Jovanović Stojanov S, Podolski Renić A, Milutinović M. Isorhamnetin Modulates Drug-Resistance-Related Biomarkers in Colon Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136208
BibTeX
@article{Radenkovi2025,
author = {Radenković, Nikola and Milenković, Dejan and Nikodijević, Danijela and Jovanović Stojanov, Sofija and Podolski Renić, Ana and Milutinović, Milena},
title = {Isorhamnetin Modulates Drug-Resistance-Related Biomarkers in Colon Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136208}
}
EUVIMED